News Details

View all news

DNA Vaccine Developer Inovio Biomedical Changes Name to Inovio Pharmaceuticals

May 17, 2010
BLUE BELL, PA--(BUSINESS WIRE)--May 17, 2010-- Inovio Biomedical Corporation (NYSE Amex: INO), a leader in the development of new preventive and therapeutic vaccines against cancers and infectious diseases, announced today that it has changed its corporate name to Inovio Pharmaceuticals, Inc. by filing a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware on May 14, 2010. Inovio’s trading symbol remains the same.

“In the last year Inovio has made great strides in advancing its DNA vaccines for influenza, HIV and cancer and its proprietary vaccine delivery technology. The new name better reflects the company’s product development leadership in unlocking the promise of DNA vaccines,” said Dr. J. Joseph Kim, President & CEO.

The CUSIP number for the company's common stock remains the same. Holders of stock certificates bearing the name "Inovio Biomedical Corporation" may continue to hold them and will not be required to exchange them for new certificates or take any other action.

About Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals is focused on the development of a new generation of vaccines, called DNA vaccines, to prevent and treat cancers and infectious diseases. The company’s SynConTM “universal” vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. Inovio’s proprietary electroporation delivery technology has been shown by initial human data to be safe and significantly increase gene expression and immune responses. Inovio’s clinical programs include HPV/cervical cancer (therapeutic), avian flu, and HIV vaccines. Inovio is developing its universal influenza vaccines in collaboration with scientists from the University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, and NIH’s Vaccine Research Center. Other partners and collaborators include Merck, ChronTech, University of Southampton, National Cancer Institute, and HIV Vaccines Trial Network. More information is available at

This press release contains, in addition to historical information, forward-looking statements. Such statements are based on management’s current estimates and expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements. Inovio is providing this information as of the date of this press release, and expressly disclaims any duty to update information contained in this press release. 


Inovio Pharmaceuticals
Bernie Hertel, 858-410-3101
Richardson & Associates
Jeff Richardson, 805-491-8313

Multimedia Files:

View all news